Gene polymorphisms and serum levels of BDNF and CRH in vitiligo patients.

BACKGROUND: Vitiligo is one of the most common hypomelanoses, in which the destruction of functioning melanocytes causes depigmentation of the skin, hair and mucous membranes. The genes encrypting brain-derived neurotrophic factor (BDNF) and corticotropin releasing hormone (CRH) might be the conceivable contributors to the development of vitiligo. This study was aimed at investigation of the serum levels of BDNF and CRH as well as their selected single nucleotide polymorphisms (SNPs) in vitiligo patients in comparison with the healthy controls.
METHODS: The cross-sectional study was carried out between October 2020 and June 2021 in 93 vitiligo patients (age range from 23 to 48 years) and 132 healthy controls (age range from 24 to 52 years). The psychological status of study participants was evaluated using the Generalized Anxiety Disorder-7 (GAD-7) scale. Serum levels of BDNF and CRH were measured with the help of a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kit. Genotyping for the rs11030094 polymorphism of the BDNF gene and for the rs242924 polymorphism of the corticotropin releasing hormone receptor 1 (CRH-R1) gene was performed by a real-time polymerase chain reaction (PCR).
RESULTS: There was a significant relationship between the CRH-R1 rs242924 and BDNF rs11030094 polymorphisms and vitiligo. Moreover, serum levels of neurotransmitters differed significantly between vitiligo and control groups and were associated with the CRH-R1 rs242924 and BDNF rs11030094 SNPs.
CONCLUSIONS: Our findings demonstrated the association between CRH-R1 rs242924 and BDNF rs11030094 polymorphisms and vitiligo. Further studies need to be carried out in vitiligo patients to confirm the results observed.

1 Background

Vitiligo is an acquired pigmentary disorder of the skin and mucous membranes, which manifests as white macules that appear due to a selective loss of melanocytes [1]. According to major population surveys, the estimated global prevalence of vitiligo is 0.5–2%, which can reach 8.8% in some areas of Asia [2]. The recent evidence demonstrated the complex patterns of intrinsic and adaptive immune mechanisms, oxidative stress, and disturbance of neuronal maintenance in skin [3]. Clinically, the non-symptomatic whitish macules on skin in vitiligo patients are not as onerous as the signs of other chronic cutaneous diseases. Nevertheless, vitiligo may serve as a cause for the wide range of psychological impairments resulting in violation of mental well-being and quality of life [4-6]. To this end, the better understanding of pathophysiology of vitiligo might be achieved by investigation of the interplay between genetic, neurohumoral, and environmental factors in the onset and progression of the disease [7-10].

Brain-derived neurotrophic factor (BDNF) is the growth factor that regulates survival, differentiation, and synaptic plasticity of neurons in the central neural system as well as the peripheral nerve fibers [11]. The data on the contribution of BDNF levels to pathophysiology of different cutaneous disorders remain controversial. Some studies reported the increased BDNF levels in patients with atopic dermatitis and androgenic alopecia [12, 13]. On the contrast, by Yanik et al. [14], the serum levels of BDNF were found to be reduced in vitiligo patients. Keeping in mind the contribution of neuropsychiatric abnormalities to vitiligo development, the same results of BDNF measurements in population with mental problems are expected. The lower BDNF levels were detected in patients with stress-induced depressive and anxious behaviors [15].

Corticotropin-releasing hormone (CRH) regulates the hypothalamic-pituitary–adrenal axis (HPA) through activation of its receptor (corticotropin-releasing hormone receptor 1 (CRH-R1)). The CRH gene is also expressed in extracranial tissues, including human skin, and can be synthesized by a variety of immune cells. Human mast cells may contain sufficient amounts of CRH and other stress peptides to mediate its autoimmune and anti-inflammatory effects [16]. Expression of CRH and CRH-R1 mRNA also has been detected in cultured human melanocytes and melanoma cells [17]. Research on vitiligo demonstrated that expression of the CRH-R1 gene is increased in both vitiligo unaffected and vitiligo affected skin. Furthermore, the increased expression of CRH and CRH-R1 correlated with high scores obtained on the Social adaptation assessment scale, which can be explained by the fact that hyperactivation of the cortical-releasing system in skin increases neuroendocrine sensitivity to stress [18].

Assigning a pivotal role of the abovementioned signaling substances in skin disorders, we estimated the genes encrypting BDNF and CRH as the conceivable contributors to the development of vitiligo. Current data show that some BDNF single nucleotide polymorphisms (SNPs) are associated with neurological, psychological, and cognitive impairments [19-21]. Recently, Hennings et al. [22] reported that BDNF rs11030094 polymorphism was associated with antidepressant treatment response in patients with different mental disorders. CRH gene disturbances are also recognized as the possible risk factors for dysregulation of stress response. For instance, the CRH-R1 rs242924 polymorphism was associated with the higher incidence of panic disorders [23].

To the best of our knowledge, no previous study examined the possible role of either BDNF rs11030094 polymorphism or CRH-R1 rs242924 polymorphism as contributing factors to vitiligo. Thus, we aimed to investigate the serum levels of BDNF and CRH as well as their selected SNPs in vitiligo patients and healthy controls.

2 Materials and methods

2.1 Study population

This was a cross-sectional study of people with vitiligo and age- and sex-matched healthy comparators, which was based in the dermatology department of General Hospital # 2 in Semey City, Kazakhstan from October 1, 2020, to June 30, 2021. All vitiligo patients included in the study had a clear diagnosis of vitiligo established by their physicians and were identified via the electronic medical records. The percentage of skin lesions was calculated using the Vitiligo Extent Score (VES) online calculator [24]. The psychological status of study participants was identified using Generalized Anxiety Disorder-7 (GAD-7) scale. The GAD-7 scores range from 0 to 21, with 0–4 none, 5–9 mild, 10–14 moderate and 15 and more severe levels of anxiety symptoms [25]. The non-vitiligo (control) participants were matched by age and sex as the comparator group, and were recruited through community advertisement. All participants were enrolled in the study after giving a written informed consent. For the patient to be considered eligible for the study, the following inclusion criteria had to be met: (i) age of 16 years and older, (ii) a verified diagnosis of vitiligo, and (iii) an ability to read and understand Russian or Kazakh. Patients were ineligible for this investigation if they: (i) were physically or mentally unable to give informed consent, (ii) had a history of any psychiatric disorder, (iii) had some somatic conditions, such as heart, pulmonary diseases or diabetes mellitus that affected their mental status, (iv) had other skin problems (acne, psoriasis, eczema, etc.)., and (v) presented with autoimmune or inflammatory diseases.

The study was approved by the Ethics Committee of Semey Medical University (approval # 2; dated October 18, 2019) within guidelines established by the 1964 Declaration of Helsinki.

2.2 Blood sampling, serum BDNF and CRH level analysis

Blood sampling was performed during the daytime from 8 am, in coordination with the participants’ visits to the hospital. Five milliliters of venous blood were collected into ethylenediaminetetraacetic acid (EDTA) tube and centrifuged during 30 minutes after collection. Centrifugation was carried out at 3000 rpm for 15 minutes. Plasma and buffy coat were extracted and stored at -80°C until analysis was carried-out at the Scientific-Research Laboratory Center of Semey Medical University. Serum BDNF levels were determined with the help of a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kit for human BDNF (Cloud-Clone Corp., USA). The test was performed in accordance with the manufacturer’s instructions. Plasma BDNF levels were calculated based on a standard curve generated by serially diluted BDNF standards. An intra-assay coefficient of variance (CV) of less than 10% was considered acceptable, and the mean intra-assay CV obtained was 4.9%. The levels of CRH in the serum were also detected by an ELISA kit (Cloud-Clone Corp., USA). The test methodology followed the manufacturer’s protocol.

2.3 DNA extraction, BDNF and CRH-R1 genotyping

DNA extraction from blood samples (100 μl) was carried out with the ready-made commercial GeneJET Mini kit (Thermo Scientific, Vilnius, Lithuania) in accordance with the manufacturer’s instructions. DNA concentration was assessed using fluorometer Qubit 4 (Thermo Scientific, Walthem, MA, USA), using Invitrogen reagent kits (Thermo Fisher Scientific, Eugene, OR, USA). The isolated DNA was frozen and stored at -20 C degrees. Genotyping for the rs11030094 polymorphism of the BDNF gene and rs242924 polymorphism of the CRH-R1 gene was performed by a real-time PCR on a QuantStudio 5 (Applied biosystems, Thermo Fisher Scientific) device using ready-made mixtures of primers and TaqMan probes in the presence of the TaqMan Genotyping Master mix reagent (all reagents manufactured by Life Technologies, Foster City, CA, USA) and 10 ng of DNA in a total volume of 5 μl. The amplification program included pre-denaturation at 60 C degrees for 30 seconds, then at 95 C degrees for 10 minutes and 40 cycles at 95 C degrees for 15 seconds and finally, at 60 C degrees for 60 seconds for all SNPs.

2.4 Statistical analysis

Statistical evaluation to identify associations between polymorphisms of the CRH-R1 and BDNF genes and presence of vitiligo was carried out via Gene Expert program (http://gen-exp.ru/calculator_or.php) using the chi-squared test (χ2) and the odds ratio (OR) with 95% confidence intervals (CI). The ratio of frequencies of genotypes and alleles was checked for compliance with the Hardy-Weinberg equilibrium (HWE).

The content of CRH and BDNF neurotransmitters in blood serum was analyzed using medians and quartiles (Me, Q1 and Q3, respectively). The levels of neurotransmitters in different genotype subgroups both in patients and controls were compared using Kruskal-Wallis test. The rates of CRH and BDNF within the same genotype in vitiligo patients and healthy controls were compared using the Mann–Whitney U test. All analyses were performed using the SPSS 20.0 package at a significance level of p < 0.05.

3 Results

The baseline characteristics of cases and controls are summarized in Table 1. This study consisted of 93 vitiligo patients (age range from 23 to 48 years) and 132 healthy controls (age range from 24 to 52 years). No difference was observed between two groups according to age, gender, and ethnicity. Nearly half of the participants had a university degree. More than half of the participants were married, and the same proportion had both parents alive. The skin types II and III prevailed among both vitiligo patients and healthy controls. The GAD-7 scores were significantly higher in cases as compared with the healthy controls (p<0.001). The serum levels of BDNF and CRH are presented in S1 Fig. The correlation of ELISA levels and VES was not significant (S1 Table).

Table 1

Demographic and clinical characteristics of the study participants.

		Cases		Controls
		N	%	N	%	Statistical test	p-value
Age (years), median and 25th-75th percentile		35	23–48	38	24–52	0.752*	0.453
Gender	Females	53	57.0	76	57.6	0.008**	0.930
	Males	40	43.0	56	42.4
Ethnicity	Kazakh	83	89.2	125	94.7	3.063**	0.216
	Russian	9	9.7	7	5.3
	Other	1	1.1	0	0.0
Education level	HS or less	6	6.5	8	6.1	2.499**	0.287
	College or less	41	44.1	45	34.1
	HE or less	46	49.5	79	59.8
Marital status	Single	28	30.1	45	34.1	1.060**	0.787
	Married	53	57.0	67	50.8
	Divorced	5	5.4	10	7.6
	Widow	7	7.5	10	7.6
Having parents	Both parents are alive	50	53.8	81	61.4	1.572**	0.456
	There is only one alive parent	23	24.7	30	22.7
	No parents	20	21.5	21	15.9
Fitzpatrick skin type	1	9	9.7	16	12.1	1.392**	0.707
	2	44	47.3	65	49.2
	3	29	31.2	41	31.1
	4	11	11.8	10	7.6
GAD-7 groups	None	50	53.80	109	82.60	27.639**	<0.001
	Mild	30	32.30	22	16.70
	Moderate	8	8.60	1	0.80
	Severe	5	5.40	0	0.00

*–test of difference was Mann Whitney U-test

**–test of difference was Chi-square test

HS–Higher School; HE–Higher Education

3.1 rs242924 polymorphism

Both case and control groups were in HWE. Genotype and allele frequencies are summarized in Table 2. The T-allele and TT genotype were at risk of having vitiligo (Table 2).

Table 2

Genotype distribution and allele frequencies of CRH-R1 rs242924.

Alleles	Cases N = 93 (%)	Controls N = 132 (%)	P	OR (95% CI)
G	24 (25.3%)	52 (39.4%)	0.002	0.52 (0.34–0.79)
T	69 (74.7%)	80 (60.6%)		1.92 (1.27–2.90)
Genotypes
GG	6 (6.5%)	28 (21.2%)	0.007	0.26 (0.10–0.65)
GT	35 (37.6%)	48 (36.4%)		1.06 (0.61–1.83)
TT	52 (55.9%)	56 (42.4%)		1.72 (1.01–2.94)

P < 0.05 is significant

OR–Odds Ratio (95% CI—95% Confidence Interval)

A multiplicative model (df = 1) was used to identify the association of alleles with the disease

A general inheritance model (df = 2) was used to identify the association of genotypes with the disease

3.2 Association of rs242924 with serum CRH levels

Serum CRH levels in individual genotypes of SNP rs242924 were evaluated between the case and control groups. It was found-out that CRH level was significantly higher in TT-genotype subgroup of cases as compared with the healthy controls: 7.30 (2.41–8.84) ng/mL vs. 2.97 (1.87–4.09) ng/mL (p = 0.001) (Table 3).

Table 3

Statistical association between serum CRH levels and CRH-R1 rs242924 genotypes in the case and control groups.

Study group	GG	GT	TT	p*
Cases N = 93	5.91 (2.66–7.36)	5.91 (2.48–7.71)	7.30 (2.41–8.84)	0.37
Controls N = 132	3.19 (2.40–3.84)	3.47 (2.91–3.95)	2.97 (1.87–4.09)	0.43
p**	0.09	0.08	0.001

Data are given as Me (Q1-Q3)

p*–P value of CRH levels between GG, GT, and TT genotypes in both case and control groups

p**–P value between of CRH levels within genotype subgroup

3.3 rs11030094 polymorphism

Genotype distribution was in HWE for both case and control groups. Table 3 demonstrates the distribution of alleles and genotypes in vitiligo patients and healthy controls. The G-allele was significantly associated with the risk of vitiligo, whereas AA-genotype was found-out to be the factor decreasing the risk of the disease (Table 4).

Table 4

Genotype distribution and allele frequencies of BDNF rs11030094.

Alleles	Case	Control	р	OR (95% CI)
G	53 (57.5%)	61 (46.2%)	0.002	1.58 (1.08–2.30)
A	40 (42.5%)	71 (53.8%)		0.63 (0.43–0.93)
Genotypes
GG	28 (30.1%)	33 (25.0%)	0.01	1.29 (0.71–2.34)
GA	51 (54.8%)	56 (42.4%)		1.65(0.97–2.81)
AA	14 (15.1%)	43 (32.6%)		0.37(0.19–0.72)

P < 0.05 is significant

OR–Odds Ratio (95% CI—95% Confidence Interval)

A multiplicative model (df = 1) was used to identify the association of alleles with the disease

A general inheritance model (df = 2) was used to identify the association of genotypes with the disease

3.4 Association of rs11030094 with serum BDNF levels

There was no significant difference in serum BDNF levels among the genotypes of the case and control groups (Table 5). Healthy controls in both GG-genotype and GA-genotype subgroups had significantly lower serum BDNF levels as compared with the vitiligo patients.

Table 5

Statistical association between serum BDNF levels and BDNF rs11030094 genotypes in the case and control groups.

Study group	GG	GA	AA	p*
Case (n = 93)	2.52 (2.26–3.23)	2.62 (1.83–3.0)	2.71 (1.72–3.0)	0.77
Control (n = 132)	3.31 (2.55–4.27)	3.14 (2.17–3.89)	2.91 (2.22–4.08)	0.72
p**	0.032	0.007	0.15

Data are given as Me (Q1-Q3)

p*–P value of CRH levels between GG, GT, and TT genotypes in both case and control groups

p**–P value between of CRH levels within genotype subgroup

Discussion

The aim of our study was to investigate the serum levels of BDNF and CRH, as well as their individual SNPs, in patients with vitiligo and healthy comparators. After analyzing the laboratory data of the two groups, we were able to establish a significant relationship between the CRH-R1 rs242924 and BDNF rs11030094 polymorphisms and vitiligo. Moreover, serum levels of neurotransmitters differed significantly between vitiligo and control groups and were associated with the CRH-R1 rs242924 and BDNF rs11030094 SNPs. These findings may point to a potential role played by the aforementioned genetic variations in the development of vitiligo.

There is a wide spectrum of studies related to the investigation of CRH-R1 gene rs242924 polymorphism. Most of them focus on the abovementioned SNPs to elucidate their contribution to the pathogenesis of neuropsychological and behavioral impairments in different populations [26-28]. Some studies are mainly concerned with the polymorphism of the CRH-R1 rs242924 gene in autoimmune disease. Such, Sato et al. [29] found that T-alleles rs7209436 and rs242924 are associated with the increased prevalence of diarrhea symptoms in patients with autoimmune irritable bowel syndrome. Several studies also examined cutaneous expression of CRH and CRH-R1 by performing a skin biopsy. For instance, Cemil et al. [30] found a statistically significant increase in CRH-R1 expression in psoriatic lesions and hypothesized that CRH-R1 may play a role in the pathogenesis of psoriasis. In addition, Papadopoulou et al. [31] pointed out that chronic urticaria expresses higher levels of CRH-R1 and mast cells as compared with the normal foreskin, breast skin and cultured human keratinocytes. These results implicate the role of CRH-R1 in chronic urticaria, which is often exacerbated by stress. In the literature, there is only one report describing the role of CRH and CRH-R1 in vitiligo. The authors found a substantial rise in expression of CRH and CRH-R1 in both damaged and undamaged skin of patients with vitiligo and observed a significant direct association with stress levels [18]. To our knowledge, the present study is the first that reports on association between vitiligo and SNPs of the CRH-R1 gene. Our finding revealed that T-allele and TT-genotype were significantly associated with vitiligo, and the level of CRH was significantly higher in cases with TT-genotype subgroup. Unfortunately, there is a lack of evidence reporting the effects of the polymorphisms studied on serum levels of the mediators. Still, according to Tsartsali et al. [32], two SNP interactions (rs242941 and rs1876828 of the CRH-R1 gene) were linked to the serum cortisol levels.

It is hypothesized that BDNF is a neurotransmitter, which plays a crucial role in the up- and down regulation of different pathways controlling synaptic plasticity. Yanik et al. [14] were the first who described the reduced serum levels of BDNF in vitiligo patients as compared with the healthy controls. Our recent study also demonstrated the decreased level of serum BDNF and increased level of serum CRH in vitiligo patients in comparison with the healthy controls [33]. Unfortunately, we were unable to find studies related to the expression of BDNF rs11030094 polymorphism in skin disorders. However, there is a number of publications devoted to the investigation of BDNF rs6265 (Val66Met) gene polymorphism in non-infectious inflammatory skin diseases. For instance, Hoffjan et al. [34] considered that the variation in the BDNF rs6265 gene is unlikely to play a substantial role in the pathogenesis of atopic dermatitis (AD), even though BDNF serum levels were considered to be a useful indicator of disease activity in AD patients. Quan et al. [35] notified that the combined effects of BDNF Val66Met and higher body mass index (C25) increased the risk and clinical severity of psoriasis vulgaris in Chinese Han population.

Our data revealed the significantly lower levels of BDNF in cases from GG-genotype and GA-genotype subgroups. There is no data on associations of SNPs with serum levels of BDNF in patients with the skin disorders. Few studies described such associations between SNPs of other mediators and their blood levels. For instance, a significant association between IL-6 572 gene polymorphism and its serum level was reported in Egyptian patients with keloid [36]. Another study showed that TT genotype of IL-19 might be a hereditary risk factor for acne vulgaris development, and it was associated with elevated IL-19 serum levels, which could be a marker of acne severity [37]. Therefore, the potential significance of BDNF SNPs in the pathogenesis of skin disorders is in the process of investigation. Nevertheless, some evidence on association of vitiligo with gene polymorphisms exists. Tumor necrosis factor (TNF)-α- 308 G/A gene polymorphism was the most investigated in vitiligo patients. The recent meta-analysis of Giri et al. [38] suggested the involvement of susceptible ’A’ allele with vitiligo susceptibility in overall population, whereas the previous studies failed to reveal that TNF-α-308 G/A polymorphism is a genetic risk factor for vitiligo [39, 40].

Corticotropin-releasing hormone is one of the main neuropeptides that plays a crucial role in controlling the hypothalamic–pituitary–adrenal axis and the systemic answer to stress [41, 42]. CRH is mostly generated in the central nervous system. Nevertheless, CRH and its receptors are also expressed in numerous peripheral tissues, including skin [10]. Cutaneous CRH is assumed to control different skin functions essential for local homeostasis [43]. The effects of CRH are indirect and are conveyed through two main types of receptors called CRH-R1 and CRH-R2 [44]. In humans, CRH-R1 is mostly expressed in all major cellular populations, whereas CRH-R2 is expressed only in hair follicle keratinocytes, sebocytes, and dermal papilla fibroblasts [45, 46]. Inside the skin, CRH and its receptors are variably expressed in dependence with the cell type and presence/absence of inflammation or disease. CRH has direct immunomodulatory effects on different immune cells. CRH provokes various signaling pathways via CRH-R1 activation, which influences proliferation, differentiation, apoptosis and pro- or anti-inflammatory activities of skin cells [47]. CRH-caused activation of mast cells (via CRHR-1a) and subsequent vascular permeability significantly contribute to inflammation [48]. Such, Ziegler et al. [10] reported that numerous skin disorders like acne, AD, psoriasis, seborrhoic eczema, prurigo, urticaria, and alopecia areata can be provoked by stress, probably also being mediated by CRH. In addition, corticotropin-releasing hormone can also cause the release of melanin-destroying molecules and pro-apoptotic molecules, which makes the skin under stress vulnerable and leads to hypopigmentation, especially since melanocytes express the corticotropin-1 releasing hormone receptor [49]. Therefore, neuroimmune interactions are capable to mediate the effects of stress on the skin and may also influence the development of vitiligo [50].

Brain derived neurotrophic factor is a protein that belongs to the family of neurotrophin growth factors and is encoded by the BDNF gene. According to different studies, it has been found in the central and peripheral parts of the nervous system. This protein plays an important reinforcing role in the growth, differentiation and maintenance of neurons, allowing their longer survival [51]. Mental distress reduces BDNF level through activation of the hypothalamic-pituitary-adrenal axis. In addition, stress may cause the strain of sympathetic-adrenal-medullary axis, which increases the levels of cortisol and neuroinflammatory cytokines and reduces BDNF levels [52]. The role of neurotrophins and their receptors in the control of cutaneous hemostasis and hair growth was extensively studied [53]. Zhai et al. [54] report that neurotrophins mediate proliferative and survival signals in epidermal keratinocytes and, accordingly, influence proliferation and survival of melanocytes. Furthermore, some authors hypothesized that reduced serum BDNF levels may be an etiologic factor for the development of vitiligo and may also be an indicator of future psychiatric comorbidity in this category of patients [14].

This study has a number of limitations that have to be discussed. The major limitation comes from its nature of a cross-sectional study, so it was not possible to determine a cause-and-effect relationship between the variables. Second, we utilized the ELISA kit that detected serum BDNF levels without identification of precursor and mature forms of this neuropeptide [14]. In addition, the sample size was rather modest. Still, we believe that our results might be confirmed on samples involving more cases and controls. Nevertheless, our study has several strengths. To our knowledge, this is the first investigation of CRH-R1 rs242924 and BDNF rs11030094 polymorphisms in subjects with vitiligo. Also, we compared the serum levels of neurotransmitters with regard to the genotype subgroups of SNPs. At last, we explored a possible contribution of CRH-R1 and BDNF gene variations to the pathogenesis of vitiligo. Our results indicated the association of both CRH-R1 rs242924 and BDNF rs11030094 polymorphisms with the risk of vitiligo occurrence, but more research is certainly needed to confirm these results.

Serum neurotransmitters levels (ng/ml) between controls and cases.

(TIFF)

Click here for additional data file.

Correlation analysis of BDNF, CRH levels and VES score.

(TIFF)

Click here for additional data file.

(XLSX)

Click here for additional data file.

26 Apr 2022

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Livia D'Angelo

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following in the Funding Section of your manuscript:

"This research was carried out as the part of PhD project"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"This research was carried out as the part of PhD project"

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Assiya Kussainova and colleagues present an intersting question evalauting the serumm concentrations and polymorphisms in Brain-derived neurotrophic factor (BDNF) and Corticotropin releasing hormone (CRH) in relation to presence or absence of vitiligo.

Major comment

In the introduction psychological or psychiatric disorders are suggested to contribute to the etiology of vitiligo. I would suggest to the authors to rephrase this and stick to the concept psychological disorders may result from vitiligo in accordance with the references given. In the current phrasing the suggestion by the authors is not supported by the references given

The authors should add a brief discussion on the neuroedocine inflammatory axis iin the introduction to introduce their hypothesis. such as Sternberg EM. J Endocrinol. 2001

In the methods no infromation is provided on the psychological status of the vitiligo patients. In addition information on (auto)immune or inflammatory diseases in the controls is lacking. This should be provided or at least discussed.

The authro should discuss the effects of the polymorphisms studied on serum levels of the mediators as previosuly reported in literature.

Minor comments

fulll names of the factors measured should be given in the abstract, to make it comprehensible for readers not familiar with the abreviations.

Though written in comprehensible english, the manuscript would benefit if a native english speaker would edit the text.

The discussion should focus more on the potential effects from differences in BDNF and CRH expression levels on the neuroendocrine inflammatory axis, than on the association with neurological or psychiatric diseases.

Reviewer #2: 1. Please write the abstract starting with vitiligo and connect with BDNF and CRH, also please expand the full-form of BDNF and CRF.

2. Please rewrite the methodology in detail in the abstract.

3. Conclusion in the abstract is not reflecting the manuscript. Please rephrase it.

4. Please add the latest references in the introduction to describe the vitiligo (https://www.annsaudimed.net/doi/full/10.5144/0256-4947.2022.96). Please cite this reference as it is published in 2022.

5. Lane no 38/46/54/175/178/181/194/197/198/205/208/226, please update the reference as per the Plos One journal Style format. Replace the year and add the reference number.

6. Line no 70: Please add controls in the bracket after non-vitiligo

7. Please add the inclusion and exclusion criteria of cases and controls in detail

8. Please add the italics form for any name of the gene used in this study?

9. Lane no 107: What do you mean by 384 line number?

10. Hardy Weinberg Equilibrium, Authors can add the full form and add abbreviated form for using more than 1 time

11. Authors can add the genetic models in Both tables 2 and 4.

12. Elisa levels can be shown in the figure (Please use R/Python/Any other software)

13. Please add about BDNF and CRH and how it is correlated to Vitiligo?

14. Please add any meta-analysis studies if applicable?

15. Please focus on limitations of this study.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Michiel van der Flier

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

17 May 2022

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

Dear Editor,

Thank you for considering our manuscript for publication in PLOS ONE. We did our best to respond to all comments made and to amend the manuscript accordingly.

We have removed the following information from the "Funding" section: This research was carried out as the part of PhD project and added: The author(s) received no specific funding for this work.

3. Thank you for stating the following in the Funding Section of your manuscript:

"This research was carried out as the part of PhD project"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"This research was carried out as the part of PhD project"

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Kindly see the changes listed below to evaluate the work done by us.

Reviewer 1

Assiya Kussainova and colleagues present an intersting question evalauting the serumm concentrations and polymorphisms in Brain-derived neurotrophic factor (BDNF) and Corticotropin releasing hormone (CRH) in relation to presence or absence of vitiligo.

Thank you very much for reviewing our manuscript and for your thoughtful comments. Your suggestions are very valuable and helped us to improve the quality of our manuscript significantly.

We highlighted all changes made in yellow.

In the introduction psychological or psychiatric disorders are suggested to contribute to the etiology of vitiligo. I would suggest to the authors to rephrase this and stick to the concept psychological disorders may result from vitiligo in accordance with the references given. In the current phrasing the suggestion by the authors is not supported by the references given

Thank you. Done. As proposed, we introduced the following changes:

Nevertheless, vitiligo may serve as a cause for is strongly associated with the wide range of psychological impairments resulting in violation of mental well-being and quality of life [4-6]

The authors should add a brief discussion on the neuroedocine inflammatory axis in the introduction to introduce their hypothesis. such as Sternberg EM. J Endocrinol. 2001

Done. We have added the following information to the "Introduction" section using recommended reference: Corticotropin-releasing hormone (CRH) regulates the hypothalamic-pituitary–adrenal axis (HPA) through activation of its receptor (corticotropin-releasing hormone receptor 1 (CRH-R1)). The CRH gene is also expressed in extracranial tissues, including human skin, and can be synthesized by a variety of immune cells. Human mast cells may contain sufficient amounts of CRH and other stress peptides to mediate its autoimmune and anti-inflammatory effects [16]. Expression of CRH and CRH-R1 mRNA also has been detected in cultured human melanocytes and melanoma cells [17]. Research on vitiligo demonstrated that expression of the CRH-R1 gene is increased in both vitiligo unaffected and vitiligo affected skin. Furthermore, the increased expression of CRH and CRH-R1 correlated with high scores obtained on the Social adaptation assessment scale, which can be explained by the fact that hyperactivation of the cortical-releasing system in skin increases neuroendocrine sensitivity to stress [18].

In the methods no information is provided on the psychological status of the vitiligo patients.

Done. We have entered the following information in the "Materials and Methods” section:

The psychological status of study participants was identified using Generalized Anxiety Disorder-7 (GAD-7) scale. The GAD-7 scores range from 0 to 21, with 0-4 none, 5-9 mild, 10-14 moderate and 15 and more severe levels of anxiety symptoms [25].

In addition information on (auto)immune or inflammatory diseases in the controls is lacking. This should be provided or at least discussed.

Thank you. To overcome this drawback, we added this information to the “Study population section”:

Patients were ineligible for this investigation if they were (i) physically or mentally unable to give informed consent, (ii) had a history of any psychiatric disorder, (iii) had some somatic conditions, such as heart, pulmonary diseases or diabetes mellitus that affected their mental status, (iv) had other skin problems (acne, psoriasis, eczema, etc.)., and (v) presented with autoimmune or inflammatory diseases.

The authro should discuss the effects of the polymorphisms studied on serum levels of the mediators as previosuly reported in literature.

Done. We added the following piece of information to the “Discussion” section:

Unfortunately, there is a lack of evidence reporting the effects of the polymorphisms studied on serum levels of the mediators. Two SNP interactions (rs242941 and rs1876828 of the CRH-R1 gene) were linked to the serum cortisol levels [32].

There is no data on associations of SNPs with serum levels of BDNF in patients with the skin disorders. Few studies described such associations between SNPs of other mediators and their blood levels. For instance, a significant association between IL-6 572 gene polymorphism and its serum level was reported in Egyptian patients with keloid [36]. Another study showed that TT genotype of IL-19 might be a hereditary risk factor for acne vulgaris development, and it was associated with elevated IL-19 serum levels, which could be a marker of acne severity [37].

fulll names of the factors measured should be given in the abstract, to make it comprehensible for readers not familiar with the abreviations

Thank you. Done.

The genes encrypting brain-derived neurotrophic factor (BDNF) and corticotropin releasing hormone (CRH) might be the conceivable contributors to the development of vitiligo. …… Genotyping for the rs11030094 polymorphism of the BDNF gene and rs242924 of the corticotropin releasing hormone receptor 1 (CRH-R1) gene was performed by real-time polymerase chain reaction (PCR) ……

Though written in comprehensible english, the manuscript would benefit if a native english speaker would edit the text.

Done. We didn’t highlight the areas of improvement as in this case the entire manuscript would be highlighted.

The discussion should focus more on the potential effects from differences in BDNF and CRH expression levels on the neuroendocrine inflammatory axis, than on the association with neurological or psychiatric diseases.

We addressed the issue of information overload related to the link between neurotransmitters and mental disorders and added the following pieces of information to the “Discussion” section: The variations of BDNF BDNF gene were described in several studies related to the impairment of the essential brain functions. Honea et al. (2013) [28] revealed that BDNF BDNF rs11030094 polymorphism was associated with cognitive decline in the patients with Alzheimer’s disease. Warburton et al. (2016) [17] linked BDNF BDNF rs11030094 SNP to memory dysfunction in patients with newly diagnosed epilepsy. The recent study of Hennings et al. (2019) [20] reported on the association between BDNF BDNF rs11030094 polymorphism and antidepressant response in subjects with major depressive disorder.

Our recent study also demonstrated the decreased level of serum BDNF and increased level of serum CRH in vitiligo patients in comparison with the healthy controls [33].

BDNF signaling may be engaged in affective behavior in the form of environmental stresses that cause depression, as well as reduce BDNF mRNA [42]. Based on this, BDNF is extensively investigated in neuropsychiatric diseases such as schizophrenia, severe depressive disorder, MDD, bipolar disorder and various addictions [43]. In the majority of these studies psychiatric disorders were found to be associated with decreased BDNF levels. Moreover, other reports have demonstrated that adequate efficient therapy improves BDNF levels in these patients [44].

Mental distress reduces BDNF level through activation of the hypothalamic-pituitary-adrenal axis. In addition, stress may cause the strain of sympathetic-adrenal-medullary axis, which increases the levels of cortisol and neuroinflammatory cytokines and reduces BDNF levels [52].

Reviewer 2

Thank you very much for reviewing our manuscript. Your comments helped us to improve its quality.

We highlighted all changes made in yellow

1. Please write the abstract starting with vitiligo and connect with BDNF and CRH, also please expand the full-form of BDNF and CRF.

Done. As proposed, we introduced the following changes: Vitiligo is one of the most common hypomelanoses, in which the destruction of functioning melanocytes causes depigmentation of the skin, hair and mucous membranes.

The genes encrypting brain-derived neurotrophic factor (BDNF) and corticotropin releasing hormone (CRH) might be the conceivable contributors to the development of vitiligo.

2. Please rewrite the methodology in detail in the abstract.

Done:

The cross-sectional study was carried out between October 2020 and June 2021 in 93 vitiligo patients (age range from 23 to 48 years) and 132 healthy controls (age range from 24 to 52 years). The psychological status of study participants was evaluated using the Generalized Anxiety Disorder-7 (GAD-7) scale. Serum levels of BDNF and CRH were measured with the help of a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kit. Genotyping for the rs11030094 polymorphism of the BDNF gene and for the rs242924 polymorphism of the corticotropin releasing hormone receptor 1 (CRH-R1) gene was performed by a real-time polymerase chain reaction (PCR).

3. Conclusion in the abstract is not reflecting the manuscript. Please rephrase it.

Thank you. We rewrote the conclusion as recommended:

These findings may point to a potential role for the aforementioned genetic variations in the development of vitiligo.

Our findings demonstrated the association between CRH-R1 rs242924 and BDNF rs11030094 polymorphisms and vitiligo. Further studies need to be carried out in vitiligo patients to confirm the results observed.

4. Please add the latest references in the introduction to describe the vitiligo (https://www.annsaudimed.net/doi/full/10.5144/0256-4947.2022.96).

Thank you. We have removed previous information from the text and replaced it by the following statement: Vitiligo is a chronic autoimmune skin disease affecting 0.5%-2% of population worldwide [1].

Vitiligo is an acquired pigmentry disorder of the skin and mucous membranes which manifests as white macules due to selective loss of melanocytes [1].

Please cite this reference as it is published in 2022.

Done. 1. Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236(6):571-592. doi: 10.1159/000506103. Epub 2020 Mar 10. PMID: 32155629.

1. Saif GB, Khan IA. Association of genetic variants of the vitamin D receptor gene with vitiligo in a tertiary care center in a Saudi population: a case-control study. Ann Saudi Med. 2022 Mar-Apr;42(2):96-106. doi: 10.5144/0256-4947.2022.96. Epub 2022 Apr 7. PMID: 35380061; PMCID: PMC8982003.

5. Lines no 38/46/54/175/178/181/194/197/198/205/208/226, please update the reference as per the Plos One journal Style format. Replace the year and add the reference number.

Done.

6. Line no 70: Please add controls in the bracket after non-vitiligo

Done:

The non-vitiligo (control) participants were matched by age and sex as the comparator group, and were recruited through community advertisement.

7. Please add the inclusion and exclusion criteria of cases and controls in detail

Thank you. Done:

For the patient to be considered eligible to take part in the study, the following inclusion criteria had to be met: (i) age of 16 years and older, (ii) a verified diagnosis of vitiligo, and (iii) an ability to read and understand Russian or Kazakh. Patients were ineligible for this investigation if they were (i) physically or mentally unable to give informed consent, (ii) had a history of any psychiatric disorder, (iii) had some somatic conditions, such as heart, pulmonary diseases or diabetes mellitus that affected their mental status, (iv) had other skin problems (acne, psoriasis, eczema, etc.)., and (v) presented with autoimmune or inflammatory diseases.

8. Please add the italics form for any name of the gene used in this study?

Thank you very much. Done.

9. Line no 107: What do you mean by 384 line number?

Thank you. We have removed this information from the text: “….and 10 ng of DNA in a total volume of 5 µl. in 384-well plates (Roche, Indianapolis, IN, USA).”

10. Hardy Weinberg Equilibrium, Authors can add the full form and add abbreviated form for using more than 1 time.

Done:

Both case and control groups were in Hardi-Weinberg equilibrium HWE.

11. Authors can add the genetic models in Both tables 2 and 4.

Thank you. Done.

Table 2. Genotype distribution and allele frequencies of CRH-R1 CRH-R1 rs242924

Alleles Cases

N = 93 (%) Controls

N = 132 (%) P OR (95% CI)

G 24 (25.3%) 52 (39.4%) 0.002 0.52 (0.34-0.79)

T 69 (74.7%) 80 (60.6%) 1.92 (1.27-2.90)

Genotypes

GG 6 (6.5%) 28 (21.2%)

0.007 0.26 (0.10-0.65)

GT 35 (37.6%) 48 (36.4%) 1.06 (0.61-1.83)

TT 52 (55.9%) 56 (42.4%) 1.72 (1.01-2.94)

Table 4. Genotype distribution and allele frequencies of BDNF BDNF rs11030094

Alleles Case Control р OR (95% CI)

G 53 (57.5%) 61 (46.2%) 0.002 1.58 (1.08-2.30)

A 40 (42.5%) 71 (53.8%) 0.63 (0.43-0.93)

Genotypes

GG 28 (30.1%) 33 (25.0%)

0.01 1.29 (0.71-2.34)

GA 51 (54.8%) 56 (42.4%) 1.65(0.97-2.81)

AA 14 (15.1%) 43 (32.6%) 0.37(0.19-0.72)

12. Elisa levels can be shown in the figure (Please use R/Python/Any other software)

We have added this information to the Supplement materials:

The serum levels of BDNF and CRH are presented on S1 Fig.

13. Please add about BDNF and CRH and how it is correlated to Vitiligo?

Done. We have added this information to the “Materials and methods” section: The percentage of skin lesions was calculated using the Vitiligo Extent Score (VES) online calculator [24].

The correlation of ELISA levels and VES was not significant (S1 Table). – “Result” section

to the Supplement materials:

S1 Table. Correlation analysis of BDNF, CRH levels and VES score

BDNF CRH

VES score r -.031 -.005

p-value .769 .961

14. Please add any meta-analysis studies if applicable?

Thank you. We have added the following information to the

"Discussion" section:

Nevertheless, some evidence on association of vitiligo with gene polymorphisms exists. Tumor necrosis factor (TNF)-α- 308 G/A gene polymorphism was the most investigated in vitiligo patients. The recent meta-analysis of Giri et al. [38] suggested the involvement of susceptible 'A' allele with vitiligo susceptibility in overall population, whereas the previous studies failed to reveal that TNF-α-308 G/A polymorphism is a genetic risk factor for vitiligo [39, 40].

15. Please focus on limitations of this study.

Thank you. We have added the following information to the

"Discussion" section:

This study has a number of limitations that have to be discussed. The major limitation comes from its nature of a cross-sectional study, so it was not possible to determine a cause-and-effect relationship between the variables. Second, we utilized the ELISA kit that detected serum BDNF levels without identification of precursor and mature forms of this neuropeptide [14]. In addition, the sample size was rather modest. Still, we believe that our results might be confirmed on samples involving more cases and controls.

Submitted filename: Response to Reviewers PlosOne.docx

Click here for additional data file.

7 Jul 2022

Gene polymorphisms and serum levels of BDNF and CRH in vitiligo patients

PONE-D-22-07470R1

Dear Dr. Kassym,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Livia D'Angelo

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The authors have worked very hard to justified all the raised comments. Therefore, the manuscript can be accepted in the current form.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: Dr. Imran Ali Khan

21 Jul 2022

PONE-D-22-07470R1

Gene polymorphisms and serum levels of BDNF and CRH in vitiligo patients

Dear Dr. Kassym:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Livia D'Angelo

Academic Editor

PLOS ONE